Mechanisms of Treatment Resistance: Molecular and Clinical Examples for Radio- and Chemotherapy

  • Carsten Nieder
Part of the Medical Radiology book series (MEDRAD)


The clinical experience from numerous well-controlled large-scale studies trying to improve the results of radioand pharmacotherapy of advanced malignant tumors by, e. g., dose escalation and/or addition of new drugs or other treatment modifiers suggests that great expectations based on sound rationales often result in small improvements of outcome. This has led to experimental and translational studies of the mechanisms that allow cancer cells to escape cytotoxic treatment or develop resistance. The present chapter summarizes our current knowledge on selected mechanisms and pathways, e.g., related to DNA damage repair.


Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Mutant Ataxia Telangiectasia Mutate Breast Cancer Resistance Protein Epidermal Growth Factor Receptor Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allan LA, Morrice N, Brady S, et al (2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5:647–654PubMedCrossRefGoogle Scholar
  2. Bassett EA, Wang W, Rastinejad F, El-Deiry WS (2008) Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 14:6376–6386PubMedCrossRefGoogle Scholar
  3. Begg AC (1990) Cisplatin and radiation: interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 19:1183–1189PubMedGoogle Scholar
  4. Belanich M, Pastor M, Randall T, et al (1996) Retrospective study of the correlation between DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56:783–788PubMedGoogle Scholar
  5. Bianco C, Tortora G, Bianco R, et al (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3250–3258PubMedGoogle Scholar
  6. Borst P, Jonkers J, Rottenberg S (2007) What makes tumors multidrug resistant? Cell Cycle 6:2782–2787PubMedGoogle Scholar
  7. Caro AA, Cederbaum AI (2006) Role of phosphatidylinositol 3-kinase/AKT as a survival pathway against CYP2E1-dependent toxicity. J Pharmacol Exp Ther 318:360–372PubMedCrossRefGoogle Scholar
  8. Chen FL, Xia W, Spector NL (2008) Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 14:6730–6734PubMedCrossRefGoogle Scholar
  9. Chinnaiyan P, Huang S, Vallabhaneni G, et al (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65:3328–3335PubMedGoogle Scholar
  10. Choudhury A, Cuddihy A, Bristow RG (2006) Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 16:51–58PubMedCrossRefGoogle Scholar
  11. Dent P, Reardon DB, Park JS, et al (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10:2493–2506PubMedGoogle Scholar
  12. Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26:2839–2845PubMedCrossRefGoogle Scholar
  13. Friedman HS, McLendon RE, Kerby T, et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMedGoogle Scholar
  14. Garcia J, Riely GJ, Nafa K, Ladanyi M (2008) KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Semin Diagn Pathol 25:288–294PubMedCrossRefGoogle Scholar
  15. Grethe S, Porn-Ares MI (2006) p38 MAPK regulates phosphorylation of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial apoptosis. Cell Signal 18:531–540PubMedCrossRefGoogle Scholar
  16. Hagan M, Yacoub A, Dent P (2004) Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res 10:5724–5731PubMedCrossRefGoogle Scholar
  17. Harari PM (2007) Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer. Int J Radiat Oncol Biol Phys 69:S25–27PubMedGoogle Scholar
  18. Hegi ME, Diserens AC, Gorlia T, et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRefGoogle Scholar
  19. Hiro J, Inoue Y, Toiyama Y, et al (2008) Mechanism of resistance to chemoradiation in p53 mutant human colon cancer. Int J Oncol 32:1305–1310PubMedGoogle Scholar
  20. Horton JK, Watson M, Stefanick DF, et al (2008) XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 18:48–63PubMedCrossRefGoogle Scholar
  21. Hutcheson IR, Knowlden JM, Jones HE, et al (2006) Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocr Relat Cancer 13(suppl 1):S89–S97PubMedCrossRefGoogle Scholar
  22. Jeggo PA, Löbrich M (2006) Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability. DNA Repair (Amst) 5:1192–1198CrossRefGoogle Scholar
  23. Kao J, Rosenstein BS, Peters S, Milano MT, Kron SJ (2005) Cellular response to DNA damage. Ann N Y Acad Sci 1066:243–258PubMedCrossRefGoogle Scholar
  24. Kuo MT (2009) Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 11:99–133PubMedCrossRefGoogle Scholar
  25. Kwak EL, Sordella R, Bell DW, et al (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665–7670PubMedCrossRefGoogle Scholar
  26. Kyndi M, Sørensen FB, Knudsen H, et al (2008) Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. Acta Oncol 47:608–617PubMedCrossRefGoogle Scholar
  27. Maeda K, Sugiyama Y (2008) Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 23:223–235PubMedCrossRefGoogle Scholar
  28. Majumdar AP, Du J (2006) Phosphatidylinositol 3-kinase/Akt signaling stimulates colonic mucosal cell survival during aging. Am J Physiol Gastrointest Liver Physiol 290:G49–G55PubMedCrossRefGoogle Scholar
  29. Marcucci G, Byrd JC, Dai G, et al (2003) Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101:425–432PubMedCrossRefGoogle Scholar
  30. Miller EM, Kinsella TJ (1992) Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 52:1687–1694PubMedGoogle Scholar
  31. Nieder C, Petersen S, Petersen C, Thames HD (2000) The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 26:67–73PubMedCrossRefGoogle Scholar
  32. Nieder C, Adam M, Grosu AL (2006) Combined modality treatment of glioblastoma multiforme: the role of temozolomide. Rev Recent Clin Trials 1:43–51PubMedCrossRefGoogle Scholar
  33. Oltersdorf T, Elmore SW, Shoemaker AR, et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681PubMedCrossRefGoogle Scholar
  34. Osaki M, Kase S, Adachi K, et al (2004) Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 130:8–14PubMedCrossRefGoogle Scholar
  35. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653–1664PubMedGoogle Scholar
  36. Reed JC (1998) Bcl-2 family proteins. Oncogene 17:3225–3236PubMedCrossRefGoogle Scholar
  37. Rodemann HP, Dittmann K, Toulany M (2007) Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83:781–791PubMedCrossRefGoogle Scholar
  38. Schimmer AD, Welsh K, Pinilla C, et al (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5:25–35PubMedCrossRefGoogle Scholar
  39. Shvartsman SY, Hagan MP, Yacoub A, et al (2002) Autocrine loops with positive feedback enable context-dependent cell signaling. Am J Physiol Cell Physiol 282:C545–C559PubMedGoogle Scholar
  40. Stewart DJ, Chiritescu G, Dahrouge S, et al (2007) Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 33:101–137PubMedCrossRefGoogle Scholar
  41. Thames HD, Petersen C, Petersen S, Nieder C, Baumann M (2002) Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. Strahlenther Onkol 178:411–421PubMedCrossRefGoogle Scholar
  42. Thomas RK, Greulich H, Yuza Y, et al (2005) Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol 70:73–81PubMedCrossRefGoogle Scholar
  43. Tournier C, Hess P, Yang DD, et al (2000) Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288:870–874PubMedCrossRefGoogle Scholar
  44. Turner JG, Sullivan DM (2008) CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 15:2648–2655PubMedCrossRefGoogle Scholar
  45. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768PubMedCrossRefGoogle Scholar
  46. Von Bossanyi P, Diete S, Dietzmann K, et al (1997) Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol 94:605–611PubMedCrossRefGoogle Scholar
  47. von Gise A, Lorenz P, Wellbrock C, et al (2001) Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 21:2324–2336CrossRefGoogle Scholar
  48. Wang JL, Liu D, Zhang ZJ, et al (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 97:7124–7129PubMedCrossRefGoogle Scholar
  49. Williams JR, Zhang Y, Zhou H, et al (2008) A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. Int J Radiat Biol 84:253–264PubMedCrossRefGoogle Scholar
  50. Xia Z, Dickens M, Raingeaud J, et al (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326–1331PubMedCrossRefGoogle Scholar
  51. Yacoub A, McKinstry R, Hinman D, et al (2003) Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159:439–452PubMedCrossRefGoogle Scholar
  52. Yang LX, Douple EB, O’Hara JA, Wang HJ (1995) Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation. Radiat Res 143:309–315PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Carsten Nieder
    • 1
  1. 1.Department of MedicineNordlandssykehuset HFBodøNorway

Personalised recommendations